Your browser is no longer supported. Please, upgrade your browser.
Settings
GNMK GenMark Diagnostics, Inc. daily Stock Chart
GNMK [NASD]
GenMark Diagnostics, Inc.
Index- P/E- EPS (ttm)-1.14 Insider Own3.30% Shs Outstand54.40M Perf Week-1.22%
Market Cap658.78M Forward P/E- EPS next Y-0.60 Insider Trans-5.37% Shs Float51.51M Perf Month-1.06%
Income-51.60M PEG- EPS next Q-0.32 Inst Own91.00% Short Float12.26% Perf Quarter-5.98%
Sales50.70M P/S12.99 EPS this Y-14.60% Inst Trans0.23% Short Ratio18.36 Perf Half Y-1.94%
Book/sh0.58 P/B20.88 EPS next Y37.50% ROA-70.40% Target Price16.30 Perf Year19.90%
Cash/sh0.44 P/C27.22 EPS next 5Y-1.26% ROE-146.00% 52W Range8.03 - 13.67 Perf YTD-1.06%
Dividend- P/FCF- EPS past 5Y4.50% ROI-84.60% 52W High-11.41% Beta1.01
Dividend %- Quick Ratio1.60 Sales past 5Y58.00% Gross Margin57.30% 52W Low50.81% ATR0.36
Employees308 Current Ratio2.00 Sales Q/Q12.60% Oper. Margin-98.30% RSI (14)50.76 Volatility3.26% 3.04%
OptionableYes Debt/Eq0.74 EPS Q/Q2.20% Profit Margin- Rel Volume0.82 Prev Close12.51
ShortableYes LT Debt/Eq0.45 EarningsAug 01 AMC Payout- Avg Volume344.11K Price12.11
Recom1.70 SMA202.68% SMA50-1.86% SMA200-0.62% Volume283,318 Change-3.20%
Jun-13-17Reiterated Needham Buy $16 → $17
Jan-24-17Reiterated Needham Buy $13 → $15
Feb-24-16Reiterated Needham Buy $13 → $11
Oct-28-15Reiterated Needham Buy $16 → $13
May-06-15Reiterated Canaccord Genuity Buy $16 → $14
Apr-17-15Reiterated Canaccord Genuity Buy $17 → $16
Dec-19-13Initiated Needham Buy $17
Aug-08-13Reiterated Canaccord Genuity Buy $18 → $14
Apr-15-13Reiterated Canaccord Genuity Buy $14 → $18
Jan-15-13Reiterated Canaccord Genuity Buy $12 → $14
Jul-27-17 08:24AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : July 27, 2017 Capital Cube
Jun-29-17 04:30PM  GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Gram-Positive and Gram-Negative Panels Business Wire
Jun-13-17 07:41PM  GenMark Diagnostics Prices Upsized Public Offering of Common Stock Business Wire -8.02%
Jun-12-17 04:01PM  GenMark Diagnostics Commences Public Offering of Common Stock Business Wire
02:49PM  GenMark Diagnostics, Inc. Value Analysis (NASDAQ:GNMK) : June 12, 2017 Capital Cube
08:05AM  GenMark Receives FDA 510(k) Market Clearance for Its ePlex® Instrument and Respiratory Pathogen Panel Business Wire
Jun-09-17 08:36AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : June 9, 2017 Capital Cube
May-31-17 05:24PM  GenMark Diagnostics to Present at the 2017 William Blair Growth Stock Conference Business Wire
May-26-17 08:13AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : May 26, 2017 Capital Cube
May-05-17 04:11PM  ETFs with exposure to GenMark Diagnostics, Inc. : May 5, 2017 Capital Cube
01:45PM  Edited Transcript of GNMK earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
08:14AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : May 5, 2017 Capital Cube
May-04-17 10:04AM  GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 Capital Cube
May-03-17 05:55PM  GenMark Diagnostics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference Business Wire
May-02-17 06:16PM  GenMark Diagnostics reports 1Q loss Associated Press
08:25AM  Investor Network: GenMark Diagnostics, Inc. to Host Earnings Call Accesswire
Apr-20-17 05:32PM  CORRECTING and REPLACING GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel Business Wire
Apr-18-17 08:40PM  GenMark Diagnostics Schedules First Quarter 2017 Financial Results Conference Call for May 2, 2017 Business Wire
Apr-13-17 12:35PM  ETFs with exposure to GenMark Diagnostics, Inc. : April 13, 2017 Capital Cube
Mar-28-17 06:53PM  GenMark Diagnostics to Present at 16th Annual Needham Healthcare Conference Business Wire
Mar-07-17 01:45PM  GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Capital Cube
01:45PM  GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
Mar-04-17 01:04PM  GENMARK DIAGNOSTICS, INC. Financials
Mar-02-17 04:05PM  GenMark Diagnostics to Present at Cowen and Companys 37th Annual Health Care Conference Business Wire
Feb-28-17 07:19PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
06:38PM  GENMARK DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report
05:19PM  GenMark Diagnostics reports 4Q loss Associated Press
04:05PM  GenMark Diagnostics Reports Fourth Quarter and Full Year 2016 Results Business Wire
07:07AM  Q4 2016 GenMark Diagnostics Inc Earnings Release - After Market Close
Feb-24-17 04:49PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits
Feb-09-17 04:05PM  GenMark Diagnostics Schedules Fourth Quarter 2016 Financial Results Conference Call for February 28, 2017 Business Wire
Jan-31-17 09:31AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : January 31, 2017 Capital Cube
09:31AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : January 31, 2017
Jan-11-17 09:20AM  7 Stocks Making Big Moves With Unusual Volume TheStreet.com
09:20AM  7 Stocks Making Big Moves With Unusual Volume
Jan-10-17 10:49AM  GenMark Diagnostics, Inc. Value Analysis (NASDAQ:GNMK) : January 10, 2017 Capital Cube +11.40%
10:49AM  GenMark Diagnostics, Inc. Value Analysis (NASDAQ:GNMK) : January 10, 2017
08:11AM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
08:05AM  GenMark Announces Preliminary Q4 2016 Financial Results Business Wire
Jan-09-17 08:04AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : January 9, 2017
Dec-28-16 04:05PM  GenMark Diagnostics to Present at the 2017 J.P. Morgan Healthcare Conference Business Wire
Dec-22-16 08:05AM  GenMark Diagnostics Submits 510(k) Applications to the FDA for ePlex® Sample-to-Answer Instrument and Respiratory Pathogen Panel Business Wire
Dec-16-16 07:08AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : December 16, 2016
Dec-13-16 11:25AM  ETFs with exposure to GenMark Diagnostics, Inc. : December 13, 2016 +6.44%
Dec-11-16 04:28AM  GenMark Diagnostics, Inc (GNMK): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-23-16 01:01PM  ETFs with exposure to GenMark Diagnostics, Inc. : November 23, 2016
07:31AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : November 23, 2016
Nov-21-16 10:53AM  GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
Nov-04-16 03:36PM  Edited Transcript of GNMK earnings conference call or presentation 3-Nov-16 8:30pm GMT +9.00%
Nov-03-16 06:08PM  GenMark Diagnostics reports 3Q loss +5.97%
04:11PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:05PM  GenMark Diagnostics Reports Q3 Financial Results Business Wire
07:07AM  Q3 2016 GenMark Diagnostics Inc Earnings Release - After Market Close
Nov-02-16 08:27AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : November 2, 2016
Nov-01-16 07:07PM  GenMark Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum Business Wire
Oct-20-16 09:09PM  GenMark Diagnostics Schedules Third Quarter 2016 Financial Results Conference Call for November 3, 2016 Business Wire
Sep-28-16 10:53AM  GenMark Diagnostics Hits 52-Week High on Solid Prospects
Sep-21-16 10:36AM  ETFs with exposure to GenMark Diagnostics, Inc. : September 21, 2016
05:46AM  Can the Rally in GenMark Diagnostics (GNMK) Shares Continue?
Sep-20-16 11:48AM  GenMark Diagnostics, Inc. Value Analysis (NASDAQ:GNMK) : September 20, 2016
Sep-19-16 08:11AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : GNMK-US : September 19, 2016
Sep-16-16 03:56PM  GenMark Diagnostics (GNMK) Stock Soars, Cowen Upgrades +20.29%
12:58PM  Why GenMark Diagnostics, Inc. Is Soaring Today at Motley Fool
12:02PM  A Closer Look at Five Stocks Gaining Ground on Friday at Insider Monkey
Sep-07-16 10:43AM  ETFs with exposure to GenMark Diagnostics, Inc. : September 7, 2016
Aug-17-16 08:16AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : August 17, 2016
Aug-16-16 12:19PM  ETFs with exposure to GenMark Diagnostics, Inc. : August 16, 2016
Aug-10-16 01:24PM  GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
Jul-30-16 11:08PM  Edited Transcript of GNMK earnings conference call or presentation 28-Jul-16 8:30pm GMT
Jul-28-16 06:18PM  GenMark Diagnostics reports 2Q loss
04:11PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:05PM  GenMark Diagnostics Reports Q2 Financial Results Business Wire
07:07AM  Q2 2016 GenMark Diagnostics Inc Earnings Release - After Market Close
Jul-27-16 05:37PM  GenMark Diagnostics to Present at the 36th Annual Canaccord Genuity Growth Conference Business Wire
Jul-21-16 02:04PM  ETFs with exposure to GenMark Diagnostics, Inc. : July 21, 2016
Jul-14-16 05:12PM  GenMark Diagnostics Schedules Second Quarter 2016 Financial Results Conference Call for July 28, 2016 Business Wire
Jun-14-16 05:19PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
Jun-08-16 04:06PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Fi
04:05PM  GenMark Achieves CE Mark for its ePlex® Sample-to-Answer System Business Wire
Jun-06-16 04:10PM  GenMark Diagnostics to Present at the William Blair 36th Annual Growth Stock Conference Business Wire +7.88%
Jun-03-16 03:22PM  ETFs with exposure to GenMark Diagnostics, Inc. : June 3, 2016
May-31-16 04:51PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-06-16 10:28AM  GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q1, 2016 By the Numbers
May-03-16 09:32PM  Edited Transcript of GNMK earnings conference call or presentation 3-May-16 8:30pm GMT
04:14PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:05PM  GenMark Reports First Quarter 2016 Results Business Wire
07:07AM  Q1 2016 GenMark Diagnostics Inc Earnings Release - After Market Close
Apr-19-16 02:00PM  GenMark Diagnostics Schedules First Quarter 2016 Financial Results Conference Call for May 3, 2016 Business Wire
Mar-24-16 04:54PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
Feb-25-16 10:49AM  GenMark Diagnostics, Inc. Earnings Analysis: 2015 By the Numbers
Feb-24-16 04:57PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits -7.83%
Feb-23-16 11:37PM  Edited Transcript of GNMK earnings conference call or presentation 23-Feb-16 9:30pm GMT
05:31PM  GenMark Diagnostics reports 4Q loss
04:13PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:05PM  GenMark Reports Fourth Quarter and Full Year 2015 Results Business Wire
07:07AM  Q4 2015 GenMark Diagnostics Inc Earnings Release - After Market Close
Feb-03-16 05:19PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jan-12-16 04:08PM  GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  GenMark Announces Preliminary Q4 Financial Results and Initiation of ePlex Analytical Studies Business Wire
Jan-07-16 08:10AM  GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : January 7, 2016
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test. The company also provides ePlex instrument and RP panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results without any additional steps. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Williams Jennifer AnneSVP, Human ResourcesJun 02Sale12.893334,292197,218Jun 05 04:59 PM
Gleeson MichaelSVP, North American Com. Ops.Jun 02Sale12.893574,602293,565Jun 05 04:58 PM
Kayyem Jon FaizSVP, Research & DevelopmentJun 02Sale12.891321,701200,857Jun 05 04:58 PM
Stier EricSVP & General CounselJun 02Sale12.893103,996146,723Jun 05 04:59 PM
Mendel ScottChief Financial OfficerMay 19Sale12.892,13527,520143,079May 23 04:52 PM
MASSARANY HANYPresident and CEOMay 19Sale12.898,239106,201384,111May 23 04:51 PM
Williams Jennifer AnneSVP, Human ResourcesMay 19Sale12.891,95425,187197,551May 23 04:52 PM
Kayyem Jon FaizSVP, Research & DevelopmentMay 19Sale12.891,26516,306200,989May 23 04:52 PM
Gleeson MichaelSVP, North American Com. Ops.May 19Sale12.891,91624,697293,922May 23 04:51 PM
Stier EricSVP & General CounselMay 19Sale12.891,79223,099147,033May 23 04:51 PM
Mendel ScottChief Financial OfficerMay 16Sale13.431,26817,029145,214May 17 07:25 PM
Gleeson MichaelSVP, North American Com. Ops.May 02Sale13.343945,256295,838May 04 05:17 PM
Williams Jennifer AnneSVP, Human ResourcesMay 02Sale13.343294,389199,505May 04 05:10 PM
MASSARANY HANYPresident and CEOMay 02Sale13.341,57120,957399,750May 04 05:10 PM
Kayyem Jon FaizSVP, Research & DevelopmentMay 02Sale13.341331,774202,254May 04 05:10 PM
Mendel ScottChief Financial OfficerMay 02Sale13.342323,095162,529May 04 05:09 PM
Stier EricSVP & General CounselMay 02Sale13.343624,829148,825May 04 05:09 PM
Stier EricSVP & General CounselMar 07Sale12.182272,765149,187Mar 09 07:54 PM
MASSARANY HANYPresident and CEOMar 07Sale12.181,65320,134402,753Mar 09 07:54 PM
Gleeson MichaelSVP, North American Com. Ops.Mar 07Sale12.185256,395296,232Mar 09 07:54 PM
Kayyem Jon FaizSVP, Research & DevelopmentMar 07Sale12.183113,788202,387Mar 09 07:53 PM
Williams Jennifer AnneSVP, Human ResourcesMar 07Sale12.185256,395199,834Mar 09 07:53 PM
Williams Jennifer AnneSVP, Human ResourcesMar 03Sale12.293304,056200,359Mar 03 07:13 PM
Stier EricSVP & General CounselMar 03Sale12.293073,773149,414Mar 03 07:13 PM
Gleeson MichaelSVP, North American Com. Ops.Mar 03Sale12.293534,338296,757Mar 03 07:12 PM
Kayyem Jon FaizSVP, Research & DevelopmentMar 03Sale12.291311,610202,698Mar 03 07:13 PM
Kayyem Jon FaizSVP, Research & DevelopmentFeb 21Sale10.085,25052,920154,079Feb 21 08:02 PM
Mendel ScottChief Financial OfficerFeb 21Sale10.088,59586,638102,761Feb 21 08:02 PM
Stier EricSVP & General CounselFeb 21Sale10.087,44175,005106,596Feb 21 08:01 PM
Gleeson MichaelSVP, North American Com. Ops.Feb 21Sale10.087,95880,217252,110Feb 21 08:01 PM
MASSARANY HANYPresident and CEOFeb 21Sale10.0833,537338,053214,824Feb 21 08:02 PM
Williams Jennifer AnneSVP, Human ResourcesFeb 21Sale10.088,11681,809153,814Feb 21 08:02 PM
Mendel ScottChief Financial OfficerFeb 14Sale10.981,27413,989111,356Feb 16 05:11 PM
MASSARANY HANYPresident and CEOFeb 02Sale11.581,14213,224277,381Feb 03 05:46 PM
Stier EricSVP & General CounselFeb 02Sale11.583654,227114,037Feb 03 05:46 PM
Gleeson MichaelSVP, North American Com. Ops.Feb 02Sale11.583984,609260,068Feb 03 05:46 PM
Mendel ScottChief Financial OfficerFeb 02Sale11.582352,721112,630Feb 03 05:47 PM
Williams Jennifer AnneSVP, Human ResourcesFeb 02Sale11.583323,845161,930Feb 03 05:45 PM
Kayyem Jon FaizSVP, Research & DevelopmentFeb 02Sale11.581311,517159,329Feb 03 05:46 PM
Gleeson MichaelSVP, North American Com. Ops.Jan 19Option Exercise0.0023,7660270,035Jan 20 06:48 PM
Stier EricSVP & General CounselJan 19Option Exercise0.0022,1060123,343Jan 20 06:48 PM
Williams Jennifer AnneSVP, Human ResourcesJan 19Option Exercise0.0023,0660171,563Jan 20 06:48 PM
MASSARANY HANYPresident and CEOJan 19Option Exercise0.0069,9830350,367Jan 20 06:48 PM
Mendel ScottChief Financial OfficerJan 19Option Exercise0.0022,5640160,933Jan 20 06:49 PM
Kayyem Jon FaizSVP, Research & DevelopmentJan 19Option Exercise0.0013,6310165,178Jan 20 06:49 PM
Mendel ScottChief Financial OfficerJan 19Sale12.479,098113,452133,301Jan 20 06:49 PM
Williams Jennifer AnneSVP, Human ResourcesJan 19Sale12.479,301115,983162,262Jan 20 06:48 PM
Kayyem Jon FaizSVP, Research & DevelopmentJan 19Sale12.475,71871,303159,460Jan 20 06:49 PM
MASSARANY HANYPresident and CEOJan 19Sale12.4727,124338,236280,384Jan 20 06:48 PM
Stier EricSVP & General CounselJan 19Sale12.478,941111,494114,402Jan 20 06:48 PM
Gleeson MichaelSVP, North American Com. Ops.Jan 19Sale12.479,569119,325260,466Jan 20 06:48 PM
MASSARANY HANYPresident and CEODec 07Sale11.081,19613,252280,384Dec 09 06:00 PM
Stier EricSVP & General CounselDec 07Sale11.082282,526101,237Dec 09 06:00 PM
Kayyem Jon FaizSVP, Research & DevelopmentDec 07Sale11.083133,468151,547Dec 09 05:59 PM
Gleeson MichaelSVP, North American Com. Ops.Dec 07Sale11.085275,839246,269Dec 09 05:59 PM
Williams Jennifer AnneSVP, Human ResourcesDec 07Sale11.085275,839148,497Dec 09 06:00 PM
Williams Jennifer AnneSVP, Human ResourcesDec 05Sale11.313363,800149,024Dec 06 05:58 PM
Stier EricSVP & General CounselDec 05Sale11.313123,529101,465Dec 06 05:58 PM
Kayyem Jon FaizSVP, Research & DevelopmentDec 02Sale11.301321,492151,860Dec 06 05:58 PM
Gleeson MichaelSVP, North American Com. Ops.Dec 02Sale11.303574,034246,796Dec 06 05:58 PM
Kagnoff MichaelDirectorNov 22Buy11.802,00023,60035,048Nov 22 05:55 PM
Kagnoff MichaelDirectorNov 14Buy12.502,00025,00033,048Nov 14 05:48 PM
Williams Jennifer AnneSVP, Human ResourcesNov 09Sale12.5815,887199,858147,860Nov 14 05:48 PM
Stier EricSVP & General CounselNov 08Sale12.138,00097,040101,777Nov 10 05:37 PM
Stier EricSVP & General CounselNov 02Sale10.303673,780109,777Nov 04 05:37 PM
Kayyem Jon FaizSVP, Research & DevelopmentNov 02Sale10.301351,391151,992Nov 04 05:37 PM
Williams Jennifer AnneSVP, Human ResourcesNov 02Sale10.303333,430163,747Nov 04 05:36 PM
MASSARANY HANYPresident and CEONov 02Sale10.301,14811,824283,509Nov 04 05:36 PM
Gleeson MichaelSVP, North American Com. Ops.Nov 02Sale10.304004,120245,653Nov 04 05:37 PM
Kayyem Jon FaizSVP, Research & DevelopmentSep 07Sale8.693102,694152,127Sep 09 06:36 PM
Williams Jennifer AnneSVP, Human ResourcesSep 07Sale8.695234,545164,080Sep 09 06:35 PM
Gleeson MichaelSVP, North American Com. Ops.Sep 07Sale8.695234,545246,053Sep 09 06:35 PM
MASSARANY HANYPresident and CEOSep 07Sale8.691,18610,306286,512Sep 09 06:35 PM
Stier EricSVP & General CounselSep 07Sale8.692271,973110,144Sep 09 06:36 PM
Kayyem Jon FaizSVP, Research & DevelopmentSep 02Sale8.621331,146152,437Sep 06 06:02 PM
Williams Jennifer AnneSVP, Human ResourcesSep 02Sale8.623342,879164,603Sep 06 06:01 PM
Stier EricSVP & General CounselSep 02Sale8.623102,672110,371Sep 06 06:02 PM
Gleeson MichaelSVP, North American Com. Ops.Sep 02Sale8.623583,086246,576Sep 06 06:02 PM
Williams Jennifer AnneSVP, Human ResourcesAug 29Sale8.6324,172208,604164,937Aug 31 06:36 PM
Gleeson MichaelSVP, North American Com. Ops.Aug 22Sale9.007,50067,500246,934Aug 22 06:11 PM
Williams Jennifer AnneSVP, Human ResourcesAug 17Sale9.215,60851,627189,109Aug 22 05:46 PM
Giles Lisa M.DirectorAug 12Buy9.408237,7365,323Aug 16 06:29 PM
Williams Jennifer AnneSVP, Human ResourcesAug 02Sale9.883343,300194,717Aug 04 05:21 PM
Kayyem Jon FaizSVP, Research & DevelopmentAug 02Sale9.881351,334152,570Aug 04 05:21 PM
Gleeson MichaelSVP, North American Com. Ops.Aug 02Sale9.884003,952254,434Aug 04 05:22 PM
Stier EricSVP & General CounselAug 02Sale9.883673,626110,681Aug 04 05:20 PM
MASSARANY HANYPresident and CEOAug 02Sale9.881,14711,332289,637Aug 04 05:21 PM